Arvinas, Inc. (NASDAQ:ARVN) Shares Acquired by XTX Topco Ltd

XTX Topco Ltd lifted its position in Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 194.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 78,257 shares of the company's stock after purchasing an additional 51,658 shares during the quarter. XTX Topco Ltd owned about 0.11% of Arvinas worth $549,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ARVN. T. Rowe Price Investment Management Inc. acquired a new position in Arvinas during the fourth quarter worth $42,332,000. Boxer Capital Management LLC acquired a new position in Arvinas during the fourth quarter worth $20,294,000. Federated Hermes Inc. boosted its stake in Arvinas by 1,965.0% during the first quarter. Federated Hermes Inc. now owns 980,674 shares of the company's stock worth $6,884,000 after buying an additional 933,183 shares during the last quarter. RTW Investments LP boosted its stake in Arvinas by 19.8% during the fourth quarter. RTW Investments LP now owns 3,334,308 shares of the company's stock worth $63,919,000 after buying an additional 551,979 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC boosted its stake in Arvinas by 42.8% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 1,776,555 shares of the company's stock worth $34,057,000 after buying an additional 532,105 shares during the last quarter. Institutional investors and hedge funds own 95.19% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Leerink Partnrs lowered Arvinas from a "strong-buy" rating to a "hold" rating in a research note on Sunday, June 1st. HC Wainwright cut their price objective on Arvinas from $24.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday. Wells Fargo & Company cut their price objective on Arvinas from $19.00 to $16.00 and set an "overweight" rating on the stock in a report on Thursday. Guggenheim cut their price objective on Arvinas from $16.00 to $15.00 and set a "buy" rating on the stock in a report on Thursday. Finally, Citigroup cut their price objective on Arvinas from $10.00 to $9.50 and set a "neutral" rating on the stock in a report on Monday, May 5th. Ten analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to data from MarketBeat, Arvinas presently has a consensus rating of "Moderate Buy" and an average price target of $19.76.

Insider Activity at Arvinas

In other Arvinas news, CFO Andrew Saik sold 5,700 shares of the business's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $7.61, for a total transaction of $43,377.00. Following the transaction, the chief financial officer owned 164,401 shares in the company, valued at $1,251,091.61. The trade was a 3.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.73% of the stock is currently owned by corporate insiders.

Arvinas Stock Up 0.8%

NASDAQ ARVN traded up $0.05 during mid-day trading on Friday, hitting $6.29. The stock had a trading volume of 2,124,307 shares, compared to its average volume of 2,068,406. The company has a 50 day simple moving average of $7.52 and a 200 day simple moving average of $9.91. The company has a market cap of $461.80 million, a price-to-earnings ratio of -6.23 and a beta of 2.22. Arvinas, Inc. has a 52-week low of $5.90 and a 52-week high of $29.61.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.03. The company had revenue of $22.40 million during the quarter, compared to the consensus estimate of $34.42 million. Arvinas had a negative return on equity of 12.01% and a negative net margin of 19.47%. Arvinas's revenue was down 70.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.49) earnings per share. As a group, equities analysts anticipate that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.